Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596886 | 0.94 | DRD3 (0.40) | DRD3KDM4EMEN1POLBMAPT | |
| SCHEMBL5419965 | 0.94 | KDM4E (0.39) | DRD3KDM4EMEN1POLBMAPT | |
| SCHEMBL5410740 | 0.88 | NOS3 (0.37) | DRD3DRD2 | |
| SCHEMBL5421297 | 0.86 | DRD2 (0.40) | DRD3DRD2 | |
| SCHEMBL14594171 | 0.86 | DRD3 (0.37) | DRD3KMT2ADRD2 | |
| SCHEMBL5420304 | 0.86 | DRD2 (0.39) | DRD3DRD2 | |
| SCHEMBL5415343 | 0.85 | GPBAR1 (0.36) | KDM4EPOLBMAPT | |
| SCHEMBL5428005 | 0.85 | MTNR1A (0.37) | — | |
| SCHEMBL5596672 | 0.84 | OPRL1 (0.36) | DRD3KDM4EMAPTKMT2AOPRL1 | |
| SCHEMBL5415953 | 0.84 | KDM1A (0.37) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160894-B2 | Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-01-09 | — | — | US | claimed |
| EP-1632492-A1 | TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2006-03-08 | — | — | EP | claimed |
| US-20050096310-A1 | Tricyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096310-A1 | Tricyclic compound | MYLK3, CSNK1A1L, MYLK | DRD3 1030/4885KDM4E 3665/4885MEN1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.